Association between diabetic retinopathy and genetic variations in α2β1 integrin, a platelet receptor for collagen

Blood

Volumn 95, Issue 5, 2000, Pages 1560-1564

  Matsubara, Yumiko ^b   Murata, Mitsuru ^a   Maruyama, Taro ^b   Handa, Makoto ^b   Yamagata, Norihiko ^b   Watanabe, Gentaro ^b   Saruta, Takao ^b   Ikeda, Yasuo ^b  

^a KEIO UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; INTEGRIN; THROMBOCYTE RECEPTOR; VERY LATE ACTIVATION ANTIGEN 2;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR DENSITY; THROMBOCYTE;

EID: 0034161315     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.5.1560.005k43_1560_1564     Document Type: Article

References (42)

1. Santoro SA, Zutter MM. The α2β1 integrin: a collagen receptor on platelets and other cells. Thromb Haemost. 1995;74:813.
2. Sixma JJ, Zanten GH, Huizinga EG, et al. Platelet adhesion to collagen: an update. Thromb Haemost. 1997;78:434.
3. Moroi M, Jung SM. Platelet receptor for collagen. Thromb Haemost. 1997;78:439.
4. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11.
5. Kamata T, Puzon W, Takada Y. Identification of putative ligand binding sites within I domain of integrin α2β1 (VLA-2, CD49b/CD29). J Biol Chem. 1994;269:9659.
6. Takada Y, Hemler ME. The primary structure of the VLA-2/collagen receptor α2 subunit (platelet GPIa): homology to other integrins and the presence of a possible collagen-binding domain. J Cell Biol. 1989;109:397.
7. Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphism in the a2 gene define multiple alleles that are associated with differences in platelet α2β1 density. Blood. 1998;92;2382.
8. Kunicki TJ, Kritzik M. Annis DS, Nugent DJ. Heredity variation in platelet integrin α2β1 density is associated with two silent polymorphisms in the α2 gene coding sequence. Blood. 1997;89:1939.
9. Reiner AP, Aramaki KM, Teramura G, Gaur L. Analysis of platelet glycoprotein Ia (alpha2 integrin) allele frequencies in three North American populations reveals genetic association between nucleotide 807C/T and amino acid 505 Glu/Lys (HPA-5) dimorphisms. Thromb Haemost. 1998;80:449.
10. Carlsson LE, Santoso S, Spitzer C, Kessler C, Greinacher A. The alpha2 gene coding sequence T807/A873 of the platelet collagen receptor integrin alpha2beta1 might be a risk factor for the development of stroke in younger patients. Blood. 1999;93:3583.
11. Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999;93:2449.
12. Moshfegh K, Wuillemin WA. Redondo M, et al. Association ot two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet 1999;353:351.
13. Barnett AH. Pathogenesis of diabetic microangiopathy: an overview. Am J Med. 1991;90:67S.
14. Winocour PD. Platelet abnormalities in diabetes mellitus. Diabetes. 1992;41:26.
15. Mustard JF, Packham MA. Platelets and diabetes mellitus. N Engl J Med. 1984;311:665.
16. Rasi V, Ikkala E, Hekali R, Myllyla G. Factors affecting plasma β-thromboglobulin in diabetes mellitus. Med Biol. 1980;58:269.
17. Dallinger KJC, Jennings PE, Toop MJ, Clyde OHB, Barnet AH. Platelet aggregation and coagulation factors in insulin dependent diabetes with and without microangiopathy. Diabet Med. 1987;4:44.
18. Powell EDU, Field RA. Diabetic retinopathy and rheumatoid arthritis. Lancet. 1964;2:17.
19. Giustina A, Perini P, Desenzani P, et al. Long-term treatment with the dual antithromboxane agent Picotamide decreases microalbuminuria in normotensive type II diabetic patients. Diabetes. 1998;47:423.
20. Barnett AH, Wakelin K, Leatherdale BA, et al. Specific thromboxane synthetase inhibition and albumin excretion rate in insulin-dependent diabetes. Lancet. 1984;16:1322.
21. The TIMAD Study Group. Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol. 1990;108:1577.
22. Faronato PP, Maioli M, Tonolo G, et al. Clustering of albumin excretion rate abnormalities in Caucasian patients with NIDDM. Diabetologia. 1997;40:816.
23. Trevisan R, Viberti G. Genetic factors in the development of diabetic nephropathy. J Lab Clin Med. 1995;126:342.
24. Unkelbach K, Kalb R, Santoso S, Kroll H, Mueller-Eckhardt C, Kiefel V. Genomic RFLP typing of human platelet alloantigens Zw(PIA), Ko, Bak and Br(HPA-1, 2, 3, 5). Br J Haematol. 1995;89:169.
25. Alberti KGMM, Zimmet PZ. Definition, diagnosis, and classification of diabetes mellitus and its complications - part 1: diagnosis and classification of diabetes mellitus-provisional report of a WHO consultation. Diabet Med. 1998;5:539.
26. Olsen S. Identification of non-diabetic glomerular disease in renal biopsies from diabetics - a dilemma. Nephrol Dial Transplant. 1999;14:1846.
27. Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryocytes. Nucleic Acid Res. 1976;3:2303.
28. Hato T, Minamoto Y, Fukuyama T, Fujita S. Polymorphisms of HPA-1 through 6 on platelet membrane glycoprotein receptors are not a genetic risk factor for myocardial infarction in the Japanese population. Am J Cardiol. 1997;80:1222.
29. Tanaka S, Ohnoki S, Shibata H, Okubo Y, Yamaguchi H, Shibata Y. Gene frequencies of human platelet antigens on glycoprotein IIIa in Japanese. Transfusion. 1996;36:813.
30. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977.
31. Cohan AJ, Mcgill PD, Rossetti RG, Guberski DL, Like AA. Glomerulopathy in spontaneously diabetic rat. Diabetes. 1987;36:944.
32. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes. 1987;36:808.
33. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Korn RR. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986;314:403.
34. Patel V, Rassam S, Newsom R, Wiek J, Kohner E. Retinal blood flow in diabetic retinopathy. Brit Med J. 1992;305:678.
35. Brown DM, Steffes MW, Thibert P, Azar S, Mauer SM. Glomerular manifestations of diabetes in the BB rat. Matabolism. 1983;32:131.
36. Koya D, Jirousek MR, Lin Y, Ishii H, Kuboki K, King GL. Characterization of proteinkinase Cβ isoform activation on the gene expression of transforming growth factor-β, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest. 1997;100:115.
37. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. Human and rat mesanginal cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med. 1991;174:931.
38. Kohner EM, Patel V, Rassam SMB. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes. 1995;44:603.
39. Aiello LP, Cavallerano JD, Gardner TW, et al. Diabetic retinopathy. Diabetes Care. 1998;21:143.
40. Remuzzi G, Bertani T. Pathophisiology of progressive nephropathies. N Engl J Med. 1998;339:1448.
41. Pape AL, Gutman N, Guitton JD, Legrand Y, Muh JP. Non enzymatic glycosylation increases platelet aggregating potency of collagen from placenta of diabetic human beings. Biochem Biophys Res Commun. 1983;111:602.
42. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334:1090.